{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:16:19Z","timestamp":1790021779170,"version":"4.0.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007687","name":"Swedish Society of Medicine","doi-asserted-by":"publisher","award":["SLS-502541"],"award-info":[{"award-number":["SLS-502541"]}],"id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007687","name":"Swedish Society of Medicine","doi-asserted-by":"publisher","award":["SLS-587661"],"award-info":[{"award-number":["SLS-587661"]}],"id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.euroneuro.2019.04.003","type":"journal-article","created":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T06:53:03Z","timestamp":1557384783000},"page":"691-700","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Monotherapy vs. combination therapy for post mania maintenance treatment: A population based cohort study"],"prefix":"10.1016","volume":"29","author":[{"given":"Louise","family":"Wing\u00e5rd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Bod\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helle","family":"Kieler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1372-4262","authenticated-orcid":false,"given":"Johan","family":"Reutfors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2019.04.003_bib0001","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jad.2008.01.017","article-title":"Quetiapine and classical mood stabilizers in the long-term treatment of Bipolar Disorder: a 4-year follow-up naturalistic study","volume":"110","author":"Altamura","year":"2008","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2019.04.003_bib0002","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1017\/neu.2015.52","article-title":"Trends in the psychopharmacological treatment of bipolar disorder: a nationwide register-based study","volume":"28","author":"Bjorklund","year":"2016","journal-title":"Acta Neuropsychiatr"},{"key":"10.1016\/j.euroneuro.2019.04.003_bib0003","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jad.2013.08.024","article-title":"Is the combination of a mood stabilizer plus an antipsychotic more effective than mono-therapies in long-term treatment of bipolar disorder? A systematic review","volume":"152-154","author":"Buoli","year":"2014","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2019.04.003_bib0004","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1399-5618.2011.00974.x","article-title":"Aripiprazole in combination with lamotrigine for the long-term treatment of patients with bipolar I disorder (manic or mixed): a randomized, multicenter, double-blind study (CN138-392)","volume":"14","author":"Carlson","year":"2012","journal-title":"Bipolar Disord"},{"key":"10.1016\/j.euroneuro.2019.04.003_bib0005","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/JCP.0000000000000440","article-title":"Utilization of psychopharmacological treatment among patients with newly diagnosed bipolar disorder from 2001 to 2010","volume":"36","author":"Chang","year":"2016","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2019.04.003_bib0006","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jpsychires.2017.03.006","article-title":"Unblending borderline personality and bipolar disorders","volume":"91","author":"di Giacomo","year":"2017","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.euroneuro.2019.04.003_bib0007","first-page":"180","article-title":"The International College of Neuro-Psychopharmacology (CINP) treatment guidelines for Bipolar disorder in adults (CINP-BD-2017), part 3: the clinical guidelines","volume":"20","author":"Fountoulakis","year":"2017","journal-title":"Int. J. Neuropsychopharmacol"},{"key":"10.1016\/j.euroneuro.2019.04.003_bib0008","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jad.2007.03.003","article-title":"Prophylactic treatment response in bipolar disorder: results of a naturalistic observation study","volume":"104","author":"Garnham","year":"2007","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2019.04.003_bib0009","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jad.2010.11.037","article-title":"Effectiveness of olanzapine monotherapy and olanzapine combination treatment in the long term following acute mania\u2013results of a two year observational study in bipolar disorder (EMBLEM)","volume":"131","author":"Gonzalez-Pinto","year":"2011","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2019.04.003_bib0010","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1177\/0269881116636545","article-title":"Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology","volume":"30","author":"Goodwin","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2019.04.003_bib0011","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3109\/15622975.2013.770551","article-title":"The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder","volume":"14","author":"Grunze","year":"2013","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.04.003_bib0012","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/wps.20298","article-title":"Lithium vs. valproate vs. olanzapine vs. quetiapine as maintenance monotherapy for bipolar disorder: a population-based UK cohort study using electronic health records","volume":"15","author":"Hayes","year":"2016","journal-title":"World Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.04.003_bib0013","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2165\/11535200-000000000-00000","article-title":"The cost of relapse for patients with a manic\/mixed episode of bipolar disorder in the EMBLEM study","volume":"28","author":"Hong","year":"2010","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.euroneuro.2019.04.003_bib0014","doi-asserted-by":"crossref","first-page":"g5673","DOI":"10.1136\/bmj.g5673","article-title":"Assessment and management of bipolar disorder: summary of updated NICE guidance","volume":"349","author":"Kendall","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.euroneuro.2019.04.003_bib0015","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/bdi.12371","article-title":"Nationwide and population-based prescription patterns in bipolar disorder","volume":"18","author":"Kessing","year":"2016","journal-title":"Bipolar Disord"},{"key":"10.1016\/j.euroneuro.2019.04.003_bib0016","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/1471-244X-12-228","article-title":"Treatment and outcomes of an Australian cohort of outpatients with bipolar I or schizoaffective disorder over twenty-four months: implications for clinical practice","volume":"12","author":"Kulkarni","year":"2012","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.04.003_bib0017","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/jamapsychiatry.2017.4711","article-title":"Real-world effectiveness of pharmacologic treatments for the prevention of rehospitalization in a Finnish nationwide cohort of patients with bipolar disorder","volume":"75","author":"Lahteenvuo","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.04.003_bib0018","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2019.04.003_bib0019","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish national inpatient register","volume":"11","author":"Ludvigsson","year":"2011","journal-title":"BMC Public Health"},{"key":"10.1016\/j.euroneuro.2019.04.003_bib0020","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S2215-0366(14)70314-1","article-title":"Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis","volume":"1","author":"Miura","year":"2014","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.04.003_bib0021","doi-asserted-by":"crossref","first-page":"90","DOI":"10.4088\/JCP.14m09349","article-title":"Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness): a pragmatic 6-month trial of lithium versus quetiapine for bipolar disorder","volume":"77","author":"Nierenberg","year":"2016","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.04.003_bib0022","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1176\/appi.ajp.163.2.217","article-title":"Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)","volume":"163","author":"Perlis","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.04.003_bib0023","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/hup.2445","article-title":"Pharmacotherapy in bipolar disorders during hospitalization and at discharge predicts clinical and psychosocial functioning at follow-up","volume":"29","author":"Pompili","year":"2014","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2019.04.003_bib0024","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1007\/s10803-018-3541-x","article-title":"The clinical features of comorbid pediatric bipolar disorder in children with autism spectrum disorder","volume":"48","author":"Sapmaz","year":"2018","journal-title":"J. Autism Dev. Disord."},{"key":"10.1016\/j.euroneuro.2019.04.003_bib0025","doi-asserted-by":"crossref","first-page":"254","DOI":"10.4088\/JCP.13m08601","article-title":"A prospective 4-year naturalistic follow-up of treatment and outcome of 300 bipolar I and II patients","volume":"75","author":"Simhandl","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.04.003_bib0026","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.eurpsy.2018.09.007","article-title":"First episode psychosis and comorbid ADHD, autism and intellectual disability","volume":"55","author":"Stralin","year":"2019","journal-title":"Eur. Psychiatry."},{"key":"10.1016\/j.euroneuro.2019.04.003_bib0027","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/da.22136","article-title":"Maintenance treatment with quetiapine when combined with either lithium or divalproex in bipolar I disorder: analysis of two large randomized, placebo-controlled trials","volume":"30","author":"Suppes","year":"2013","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.euroneuro.2019.04.003_bib0028","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1192\/bjp.184.4.337","article-title":"Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone","volume":"184","author":"Tohen","year":"2004","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.04.003_bib0029","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1176\/appi.ajp.162.7.1281","article-title":"Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial","volume":"162","author":"Tohen","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.04.003_bib0030","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.4088\/JCP.11m06878","article-title":"Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study)","volume":"72","author":"Weisler","year":"2011","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.04.003_bib0031","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/pds.1294","article-title":"The new Swedish prescribed drug register\u2013opportunities for pharmacoepidemiological research and experience from the first six months","volume":"16","author":"Wettermark","year":"2007","journal-title":"Pharmacoepidemiol. Drug. Saf."},{"key":"10.1016\/j.euroneuro.2019.04.003_bib0032","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jad.2017.03.054","article-title":"Reducing the rehospitalization risk after a manic episode: a population based cohort study of lithium, valproate, olanzapine, quetiapine and aripiprazole in monotherapy and combinations","volume":"217","author":"Wingard","year":"2017","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2019.04.003_bib0033","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/hup.1240","article-title":"Aripiprazole plus divalproex for recently manic or mixed patients with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind maintenance trial","volume":"26","author":"Woo","year":"2011","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2019.04.003_bib0034","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jad.2012.11.042","article-title":"Efficacy of aripiprazole versus placebo as adjuncts to lithium or valproate in relapse prevention of manic or mixed episodes in bipolar I patients stratified by index manic or mixed episode","volume":"147","author":"Yatham","year":"2013","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2019.04.003_bib0035","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/mp.2015.158","article-title":"Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: a CANMAT randomized double-blind trial","volume":"21","author":"Yatham","year":"2016","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.04.003_bib0036","doi-asserted-by":"crossref","first-page":"155","DOI":"10.31887\/DCNS.2013.15.2\/mzimmerman","article-title":"The relationship between borderline personality disorder and bipolar disorder","volume":"15","author":"Zimmerman","year":"2013","journal-title":"Dialogues Clin. Neurosci."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X19302342?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X19302342?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:51:36Z","timestamp":1760377896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X19302342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0924977X19302342"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2019.04.003","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monotherapy vs. combination therapy for post mania maintenance treatment: A population based cohort study","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2019.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}